Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725848 | 1.00 | HCAR3 (0.43) | HCAR3AAK1NNMTHCAR2TLR8 | |
| SCHEMBL15905736 | 1.00 | HCAR3 (0.43) | HCAR3AAK1NNMTHCAR2TLR8 | |
| SCHEMBL1725107 | 0.93 | HCAR3 (0.45) | HCAR3AAK1NNMTHCAR2EPHX2 | |
| SCHEMBL15905738 | 0.93 | HCAR3 (0.45) | HCAR3AAK1NNMTHCAR2EPHX2 | |
| SCHEMBL1725108 | 0.93 | HCAR3 (0.45) | HCAR3AAK1NNMTHCAR2EPHX2 | |
| SCHEMBL1725419 | 0.88 | HCAR3 (0.41) | HCAR3NNMTHCAR2F10 | |
| SCHEMBL1725418 | 0.88 | HCAR3 (0.41) | HCAR3NNMTHCAR2F10 | |
| SCHEMBL15905735 | 0.88 | HCAR3 (0.41) | HCAR3NNMTHCAR2F10 | |
| SCHEMBL691346 | 0.84 | HCAR3 (0.62) | HCAR3HCAR2 | |
| SCHEMBL693630 | 0.83 | HCAR3 (0.50) | HCAR3HCAR2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2403849-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | Merck Serono S.A. (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | HCAR3 173/4885AAK1 1061/4885NNMT 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.